EMEA-003121-PIP01-21
Key facts
| Invented name |
Flebogamma DIF (previously Flebogammadif)
|
| Active substance |
Human normal immunoglobulin
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0094/2022
|
| PIP number |
EMEA-003121-PIP01-21
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of post-polio syndrome
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Instituto Grifols, S.A.
E-mail: areatecnica.instituto@grifols.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|